A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19.
作者信息
Volpe Massimo, Patrono Carlo
机构信息
Cardiology, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy.
Pharmacology, Catholic University School of Medicine, Rome, Italy and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Eur Heart J. 2021 Mar 14;42(11):1061-1062. doi: 10.1093/eurheartj/ehab106.
Abstract
摘要
相似文献
1
A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19.一项随机试验支持在因新冠肺炎住院期间继续使用血管紧张素转换酶抑制剂（ACEi）或血管紧张素Ⅱ受体阻滞剂（ARBs）进行治疗的建议。
Eur Heart J. 2021 Mar 14;42(11):1061-1062. doi: 10.1093/eurheartj/ehab106.
2
Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.血管紧张素转化酶抑制剂（ACEI）或血管紧张素受体阻滞剂（ARB）可能对 COVID-19 患者是安全的。
BMC Infect Dis. 2021 Jan 25;21(1):114. doi: 10.1186/s12879-021-05821-5.
3
Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.COVID-19 综合征住院后血管紧张素转换酶抑制剂或血管紧张素 II 受体拮抗剂的预先给药与生存。
J Am Heart Assoc. 2020 Nov 17;9(22):e017364. doi: 10.1161/JAHA.120.017364. Epub 2020 Oct 7.
4
Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.预测感染意大利公民中严重或致命的 COVID-19 的因素，包括血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂。
PLoS One. 2020 Jun 24;15(6):e0235248. doi: 10.1371/journal.pone.0235248. eCollection 2020.
5
COVID-19, ACEI/ARBs, and Gastrointestinal Symptoms: The Jury Is Still Out on the Association.新型冠状病毒肺炎、血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂与胃肠道症状：关于二者之间的关联尚无定论。
Gastroenterology. 2021 Apr;160(5):1896-1897. doi: 10.1053/j.gastro.2020.06.095. Epub 2020 Jul 16.
6
Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.糖尿病患者的药物警戒：一项数据驱动的分析，确定了具有不良肺部安全性特征的特定 RAS 拮抗剂，这些特征对 COVID-19 的发病率和死亡率有影响。
J Am Pharm Assoc (2003). 2020 Nov-Dec;60(6):e145-e152. doi: 10.1016/j.japh.2020.05.018. Epub 2020 Jun 1.
7
Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.血管紧张素 II 受体阻滞剂和 ACE（血管紧张素转换酶）抑制剂对 COVID-19 合并高血压患者病毒感染、炎症状态和临床结局的影响：一项单中心回顾性研究。
Hypertension. 2020 Jul;76(1):51-58. doi: 10.1161/HYPERTENSIONAHA.120.15143. Epub 2020 Apr 29.
8
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.肾素-血管紧张素-醛固酮系统抑制剂与 COVID-19 住院患者死亡风险：意大利 43000 例患者的回顾性队列研究。
Drug Saf. 2020 Dec;43(12):1297-1308. doi: 10.1007/s40264-020-00994-5.
9
Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts.血管紧张素转化酶抑制剂和血管紧张素受体阻滞剂的使用与 COVID-19 家庭接触者的较低风险相关。
PLoS One. 2021 Mar 2;16(3):e0247548. doi: 10.1371/journal.pone.0247548. eCollection 2021.
10
A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.中国 2 家中心回顾性研究：血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂在高血压合并 COVID-19 患者中的持续使用效果。
Med Sci Monit. 2020 Sep 24;26:e926651. doi: 10.12659/MSM.926651.
引用本文的文献
1
ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review.ACE2 和先天免疫在调控 SARS-CoV-2 诱导的急性肺损伤中的作用：综述。
Int J Mol Sci. 2021 Oct 25;22(21):11483. doi: 10.3390/ijms222111483.
2
Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.高血压，COVID-19 中的一个动态目标：当前观点和视角。
Circ Res. 2021 Apr 2;128(7):1062-1079. doi: 10.1161/CIRCRESAHA.121.318054. Epub 2021 Apr 1.
本文引用的文献
1
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.COVID-19 患者入院后停用与继续使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂对存活日数和出院日数的影响：一项随机临床试验。
JAMA. 2021 Jan 19;325(3):254-264. doi: 10.1001/jama.2020.25864.
2
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.COVID-19 患者住院期间继续或停用肾素-血管紧张素系统抑制剂：一项前瞻性、随机、开放标签试验。
Lancet Respir Med. 2021 Mar;9(3):275-284. doi: 10.1016/S2213-2600(20)30558-0. Epub 2021 Jan 7.
3
Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?关于肾素-血管紧张素系统抑制剂在新冠病毒后期研究中作用的系统综述：新的挑战是否已被克服？
Int J Cardiol. 2020 Dec 15;321:150-154. doi: 10.1016/j.ijcard.2020.07.041. Epub 2020 Jul 30.
4
Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension.年龄和多种合并症预测 COVID-19 患者的死亡：意大利高血压学会 SARS-RAS 研究的结果。
Hypertension. 2020 Aug;76(2):366-372. doi: 10.1161/HYPERTENSIONAHA.120.15324. Epub 2020 Jun 22.
5
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
6
Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?血管紧张素转化酶抑制剂在新冠疫情中可能发挥作用？
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):248-251. doi: 10.1093/ehjcvp/pvaa030.
7
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
Zotero 插件